免疫系统
免疫疗法
PD-L1
单克隆抗体
表位
抗原
肿瘤微环境
T细胞
癌症研究
癌症免疫疗法
免疫检查点
抗体
免疫学
细胞毒性T细胞
生物
体外
生物化学
作者
Shamaila Munir Ahmad,Troels Holz Borch,Morten Bagge Hansen,Mads Hald Andersen
标识
DOI:10.1007/s00262-015-1783-4
摘要
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.
科研通智能强力驱动
Strongly Powered by AbleSci AI